Measures of Response: RECIST, WHO, and New Alternatives
Top Cited Papers
- 10 July 2006
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (20) , 3245-3251
- https://doi.org/10.1200/jco.2006.06.5599
Abstract
RECIST (Response Evaluation Criteria in Solid Tumors) is a widely employed method introduced in 2000 to assess change in tumor size in response to therapy. The simplicity of the technique, however, contrasts sharply with the increasing sophistication of imaging instrumentation. Anatomically based imaging measurement, although supportive of drug development and key to some accelerated drug approvals, is being pressed to improve its methodologic robustness, particularly in the light of more functionally-based imaging that is sensitive to tissue molecular response such as fluorodeoxyglucose positron emission tomography. Nevertheless ready availability of computed tomography and magnetic resonance imaging machines largely assures anatomically based imaging a continuing role in clinical trials for the foreseeable future. Recent advances in image processing enabled by the computational power of modern clinical scanners open a considerable opportunity to characterize tumor response to therapy as a complement to image acquisition. Various alternative quantitative volumetric approaches have been proposed but have yet to gain wide acceptance by clinical and regulatory communities, nor have these more complex techniques shown incontrovertible evidence of greater reproducibility or predictive value of clinical events and outcome. Unless plans are created for clinical trials that incorporate the design needed to prove the added value and unique clinical utility of these novel approaches, any theoretical benefit of these more elaborate methods could remain unfulfilled.Keywords
This publication has 41 references indexed in Scilit:
- Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response CriteriaJapanese Journal of Clinical Oncology, 2003
- Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trialsCancer, 2003
- Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor ResponseJournal of Clinical Oncology, 2003
- Radiological Measurement of Breast Cancer Metastases to Lung and Liver: Comparison Between WHO (Bidimensional) and RECIST (Unidimensional) GuidelinesJournal of Computer Assisted Tomography, 2003
- Measuring the clinical response. What does it mean?European Journal Of Cancer, 2002
- Tumor size on computed tomography scansCancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional MeasurementJNCI Journal of the National Cancer Institute, 1999
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996
- Reporting results of cancer treatmentCancer, 1981